Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $56.40 Average Target Price from Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given an average recommendation of “Hold” by the seven research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $56.40.

Several equities analysts recently issued reports on PSTV shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets cut their target price on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th.

Plus Therapeutics Price Performance

Shares of Plus Therapeutics stock opened at $3.96 on Monday. The stock has a market cap of $27.26 million, a price-to-earnings ratio of -1.72 and a beta of 1.40. The firm’s 50-day moving average is $4.39 and its 200 day moving average is $5.59. Plus Therapeutics has a 1 year low of $2.90 and a 1 year high of $23.42.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.20). The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. On average, equities analysts expect that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

Large investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics during the 2nd quarter valued at about $41,000. Scientech Research LLC bought a new position in Plus Therapeutics during the third quarter valued at approximately $100,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the third quarter valued at approximately $46,000. Geode Capital Management LLC boosted its holdings in Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares during the last quarter. Finally, L1 Global Manager Pty Ltd bought a new stake in Plus Therapeutics in the 4th quarter worth approximately $1,167,000. 3.28% of the stock is currently owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.